Polatom

What Polatom does

Polatom operates as the Radioisotope Centre of Poland's National Centre for Nuclear Research (NCBJ), a government-owned state research entity headquartered in Otwock-Świerk, Poland. Founded as a division of NCBJ with the commissioning of the MARIA research reactor in 1974, the company manufactures and distributes isotope preparations for medicine, science, industry, and environmental protection. Its product portfolio spans radiopharmaceuticals (including the 99Mo/99mTc generator, SPECT imaging kits, 131I preparations, and palliative bone metastases treatments), radiochemical reagents produced from MARIA reactor-irradiated targets, sealed radiation sources (75Se, 192Ir, 60Co) for industrial radiography, and standard radioactive solutions for metrology. The company also runs a preclinical research laboratory and offers accredited calibration services.

The underlying technology platform is built around the MARIA research reactor (50 years operational as of 2024) supplemented by cyclotron-based radionuclide production, GMP-compliant radiopharmaceutical manufacturing with end-to-end quality control, and the only laboratory in Poland capable of absolute alpha, beta, and gamma radionuclide activity measurements using primary methods — a role formally recognized through its custodianship of the National Standard of Radioactive Activity since 1999. Production capacity covers 66 radiopharmaceuticals, 41 radiochemical reagents, 90 radioactivity standards products, and 3 sealed source products, totaling more than 500 catalogued items.

Polatom generates revenue through direct B2B sales with customized quotations across multiple streams: radiopharmaceutical manufacturing and distribution, radiochemical reagents, sealed radiation sources, accredited calibration/metrology services, pharmaceutical wholesale distribution of imported products (from partners such as Eckert & Ziegler, Curium, Rotop Pharmaka, DLD Diagnostika), and specialized air logistics for time-sensitive radioactive materials. Customer segments are diversified across nuclear medicine departments and hospitals (primarily diagnostic imaging and oncology therapy), research institutions and universities, industrial radiography companies, and calibration laboratories, with over 95% of Ir-192 source production exported globally and particularly strong penetration in Far East markets.

Name

Polatom

Legal name

Narodowe Centrum Badań Jądrowych Ośrodek Radioizotopów – POLATOM

Website

https://polatom.pl

Company type

Private

Founded year

1974

Operating status

Operating

Headcount range

251–500 employees

Short description

Polatom is a Polish government-owned radioisotope centre within NCBJ that manufactures and distributes radiopharmaceuticals, radiochemical reagents, sealed radiation sources, and radioactivity standards using the MARIA research reactor, supplying nuclear medicine departments, research institutions, and industrial customers globally.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Manufacturing

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

akta.pro secondary industries

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE), Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC), Radiation Safety, Dosimetry & Regulatory Compliance (Nuclear Medicine) (HLAIAGAJ)

Keywords

• Radiopharmaceutical manufacturing
• Radioisotope production
• Nuclear medicine products
• Sealed radiation sources
• Radiochemical reagents

Headquarters

HQ city

Otwock

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Radiopharmaceutical Products: Manufacturing and distribution of radiopharmaceuticals including generators, SPECT kits, radioiodine preparations, and therapeutic precursors for nuclear medicine applications.
2. Radiochemical Reagents: Production and sale of radiochemical reagents produced from targets irradiated in the MARIA research reactor, serving scientific and industrial customers.
3. Sealed Radiation Sources: Manufacturing of sealed sources (75Se, 192Ir, 60Co) for industrial radiography, non-destructive testing, and industrial process control applications.
4. Radioactivity Standards and Calibration Services: Accredited calibration laboratory services including activity measurements, reference source calibration, and metrology services for nuclear medicine facilities.
5. Imported Radiopharmaceuticals and Equipment: Import and distribution of third-party radiopharmaceuticals, diagnostic kits, closed sources, measurement and shielding equipment for nuclear medicine departments.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

Polatom manufactures and distributes radioisotope preparations, including radiopharmaceuticals (such as 99Mo/99mTc generators, SPECT kits, and 131I preparations), radiochemical reagents, sealed radiation sources (75Se, 192Ir, 60Co), and standard radioactive solutions used in nuclear medicine diagnostics, therapy, scientific research, industrial radiography, and environmental protection. The company also offers accredited calibration/metrology services and preclinical research services.

Product overview

Polatom (Narodowe Centrum Badań Jądrowych Ośrodek Radioizotopów – POLATOM) is a Polish manufacturer and distributor of isotope preparations for medicine, science, industry, and environmental protection. The product portfolio centers on radiopharmaceuticals including the 99Mo/99mTc generator, SPECT imaging kits, and 131I preparations; supported by radiochemical reagents produced from the MARIA research reactor; sealed radiation sources (75Se, 192Ir, 60Co) for industrial radiography; and standard radioactive solutions for calibration. Research and development products include GMP-grade DOTATATE, PSMA-11, PSMA-T4, and ascorbic acid for radiopharmaceutical development. The company also offers preclinical research services, logistics services for radioactive materials transport, and radioactivity standards calibration through its accredited laboratory.

Differentiator

Problem solved

Functional benefit

Products and services

• Radiopharmaceuticals (Radiofarmaceutyki)
• Radiochemical Reagents (Odczynniki radiochemiczne)
• Sealed Radiation Sources (Źródła zamknięte)
• Standard Solutions and Sources (Roztwory i Źródła wzorcowe)
• Laboratory of Preclinical Studies
• Logistic Services
• DOTATATE
• PSMA-11
• PSMA-T4 (PSMA-HYNIC)
• Ascorbic Acid

Quantifiable outcome

• Only laboratory in Poland performing absolute alpha, beta, and gamma radionuclide measurements
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• National Centre for Nuclear Research (NCBJ)coreStrategic or Co-development PartnerParent organization and consortium leader. POLATOM operates as the Radioisotope Centre within NCBJ. The CERAD project is coordinated by NCBJ with consortium partners including Warsaw University, Institute of Nuclear Chemistry and Technology, Warsaw Medical University, Jagiellonian University Collegium Medicum, and Medical University in Białystok.
• Warsaw University (Uniwersytet Warszawski)minorStrategic or Co-development PartnerCERAD consortium partner contributing to radiopharmaceutical research infrastructure development.
• Institute of Nuclear Chemistry and Technology (IChTJ)minorStrategic or Co-development PartnerCERAD consortium partner in Warsaw specializing in nuclear chemistry research.
• Warsaw Medical University (WUM)minorStrategic or Co-development PartnerCERAD consortium partner providing clinical research perspective for radiopharmaceutical development.
• Jagiellonian University Collegium MedicumminorStrategic or Co-development PartnerCERAD consortium partner contributing clinical research capabilities.
• Medical University in BiałystokminorStrategic or Co-development PartnerCERAD consortium partner supporting radiopharmaceutical research.
• Eckert & Ziegler GmbHminorChannel Partner/ Reseller/ DistributorSupplier of radiopharmaceutical products imported and distributed through POLATOM's pharmaceutical wholesale operation.
• Curium/CIS bio Int.minorChannel Partner/ Reseller/ DistributorInternational radiopharmaceutical supplier whose products complement POLATOM's product portfolio.
• Rotop Pharmaka AGminorChannel Partner/ Reseller/ DistributorRadiopharmaceutical product supplier distributed through POLATOM.
• DLD Diagnostika GmbHminorChannel Partner/ Reseller/ DistributorDiagnostic product supplier for POLATOM's import and distribution operations.
• IZOTOPminorChannel Partner/ Reseller/ DistributorIsotope product supplier included in POLATOM's supplier network.
• LOT Polish AirlinesminorOthersPrimary airline partner for air freight of radioactive materials from Warsaw Chopin Airport, enabling 24/7 logistics operations for time-sensitive radiopharmaceutical shipments.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Rotop Pharmaka: German specialist radiopharmaceutical CDMO and product supplier (Tc-99m generators, SPECT kits, therapeutic radiopharmaceuticals). Existing supplier partner of Polatom; comparable GMP manufacturing scope and nuclear medicine customer base across Europe.
• Nordion: Canadian-based supplier of medical isotopes including Mo-99 from the Bruce reactor and gamma-sterilization services. Overlapping with Polatom's Mo-99/Tc-99m generator franchise and sealed source / Co-60 industrial sterilization exposure.
• Curium: One of the world's largest nuclear medicine-focused manufacturers, producing SPECT imaging agents (Tc-99m generators, kits) and therapeutic radiopharmaceuticals. Closely comparable to Polatom across product portfolio, customer base (nuclear medicine departments), and GMP manufacturing model.
• NTP Radioisotopes (SOC Ltd): South African state-owned producer of Mo-99 and other medical/industrial radioisotopes from the SAFARI-1 research reactor. Near-identical business model to Polatom as a state-owned entity commercializing reactor-based isotope production for global export.
• IRE (Institut National des Radioéléments): Belgian producer of medical radioisotopes and radiopharmaceuticals (Mo-99, I-131, Lu-177 precursors) for global nuclear medicine supply. Directly comparable in production capabilities, European customer base, and GMP-manufactured product mix.
• Lantheus Holdings: US-listed diagnostic radiopharmaceutical specialist (DEFINITY, Xenon-133, Technecium generators) heavily focused on SPECT imaging agents and growing PSMA-PET franchise. Closely comparable to Polatom's SPECT-kit product line and direct nuclear medicine customer overlap.
• Eckert & Ziegler: German manufacturer of radioisotopes, radiopharmaceuticals and radiation therapy sources, including Lu-177 and Y-90 therapeutic products. Already a supplier partner of Polatom's wholesale operations; directly overlapping in therapeutic and industrial isotope manufacturing.

Emerging players

• Telix Pharmaceuticals: Commercial-stage theranostics company commercializing Illuccix (PSMA-PET) and advancing Lu-177 PSMA and alpha-emitter therapies. A direct emerging competitor to Polatom's PSMA-11 / DOTATATE R&D pipeline in prostate cancer and neuroendocrine tumor imaging and therapy.
• IBA (Ion Beam Applications) — Radiopharma Solutions: Cyclotron vendor and emerging radiopharma CDMO/developer (cyclone-produced Tc-99m, PET tracers). Adjacent/emerging technology overlap with Polatom's cyclotron-based production and represents both a potential alternative production-route supplier and indirect competitor.

Broad incumbents

• GE HealthCare: Global healthcare technology incumbent combining diagnostic imaging equipment (SPECT/PET scanners) with a radiopharmaceuticals portfolio (Omnipaque contrast, PET tracer network). Overlaps with Polatom on the nuclear medicine demand side and competes broadly in imaging-agent supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/polatom

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polatom